GSK, Novartis concede more ground in ACCC’s Voltaren case
Bird & Bird 2018-03-06 8:07 pmBy Cat Fredenburgh | Melbourne
Please login to bookmark Close

GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au